Marcus V Cronauer
Overview
Explore the profile of Marcus V Cronauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
657
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Goubergen J, Perina M, Handle F, Morales E, Kremer A, Schmidt O, et al.
Mol Oncol
. 2024 Sep;
19(2):496-518.
PMID: 39258426
In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. Androgen receptor splice...
2.
Guzman J, Weigelt K, Neumann A, Tripal P, Schmid B, Winter Z, et al.
BMC Cancer
. 2024 Mar;
24(1):346.
PMID: 38500100
Background: The androgen/androgen receptor (AR)-signaling axis plays a central role in prostate cancer (PCa). Upon androgen-binding the AR dimerizes with another AR, and translocates into the nucleus where the AR-dimer...
3.
Stein J, Krappe E, Kremer A, Cronauer M, Essler M, Cox A, et al.
J Cancer Res Clin Oncol
. 2024 Feb;
150(2):76.
PMID: 38310601
Purpose: Investigation of Microtubuli-associated Protein 2 (MAP2) expression and its clinical relevance in prostate cancer. Material And Methods: MAP2 expression was immunohistochemically analysed on radical prostatectomy specimens using whole block...
4.
Wambach M, Montani M, Runz J, Stephan C, Jung K, Moch H, et al.
APMIS
. 2024 Jan;
132(4):256-266.
PMID: 38288749
Human anterior gradient-2 (AGR2) has been implicated in carcinogenesis of various solid tumours, but the expression data in prostate cancer are contradictory regarding its prognostic value. The objective of this...
5.
Tolkach Y, Kremer A, Lotz G, Schmid M, Mayr T, Forster S, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139600
Background: Canonical androgen receptor (AR) signaling regulates a network of DNA repair genes in prostate cancer (PCA). Experimental and clinical evidence indicates that androgen deprivation not only suppresses DNA repair...
6.
Kaczorowski A, Chen X, Kristiansen G, Bernemann C, Hohenfellner M, Cronauer M, et al.
Cancer Treat Res Commun
. 2020 Nov;
28:100230.
PMID: 33139223
No abstract available.
7.
Kaczorowski A, Chen X, Herpel E, Merseburger A, Kristiansen G, Bernemann C, et al.
Cancer Treat Res Commun
. 2020 Jul;
24:100186.
PMID: 32619831
Background: The androgen receptor (AR) splice variant V7 (AR-V7) is an emerging marker to aid clinical decision-making in patients with castration-resistant prostate cancer (CRPC). A number of studies have shown...
8.
Steinestel J, Luedeke M, Arndt A, Schnoeller T, Lennerz J, Wurm C, et al.
Oncotarget
. 2019 Jul;
10(41):4213-4223.
PMID: 31289619
Molecular modifications of the androgen receptor (AR) can cause resistance to androgen deprivation therapy (ADT) in prostate cancer patients. Since lack of representative tumor samples hinders therapy adjustments according to...
9.
Hupe M, Hoda M, Zengerling F, Perner S, Merseburger A, Cronauer M
World J Urol
. 2018 Jun;
37(2):343-349.
PMID: 29934670
Objective: The bromodomain and extra-terminal (BET) family of proteins provides a scaffolding platform for the recruitment and tethering of transcription factors to acetylated chromatin, thereby modulating gene expression. In this...
10.
Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, et al.
Urol Oncol
. 2017 Dec;
36(4):161.e19-161.e30.
PMID: 29198908
Background: Overexpression of the androgen receptor (AR) splice variant 7 (AR-V7) has recently been reported to be associated with resistance to antihormonal therapy. Herein, we address the question whether tumor...